Latest Patent Applications News

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

Ardea Resources pushes back the completion of its Kalgoorlie Nickel Project DFS to pursue optimisation opportunities, while securing strong multi-level government backing and maintaining a robust financial position.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Temas Resources has filed a new patent for extracting chromium using its Regenerative Chloride Leach technology, broadening its critical minerals platform and commercial prospects.

Temas Resources has filed a new patent for its proprietary Regenerative Chloride Leach (RCL) process targeting vanadium extraction, broadening its critical minerals technology portfolio and reinforcing its commercial licensing ambitions.

ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.

Botanix Pharmaceuticals has received an Intention to Grant from the European Patent Office for a patent protecting its Sofdra applicator technology, potentially extending exclusivity in Europe until 2039.